Literature DB >> 22170573

Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosis.

Avo Artinyan1, Christy L Marshall, Courtney J Balentine, Daniel Albo, Sonia T Orcutt, Samir S Awad, David H Berger, Daniel A Anaya.   

Abstract

BACKGROUND: Cirrhosis is a risk factor for postoperative morbidity and mortality after general surgical procedures. However, the impact of cirrhosis on outcomes of surgical resection for gastrointestinal (GI) malignancies has not been described. The authors' objective was to characterize early postoperative and transitional outcomes in cirrhotic patients undergoing GI cancer surgery.
METHODS: Query of the National Inpatient Sample Database (2005-2008) identified 106,729 patients who underwent resection for GI malignancy; 1479 (1.4%) had cirrhosis. The association of cirrhosis with postoperative outcomes was examined. The primary outcome measure was in-hospital mortality. Secondary outcomes included length-of-stay (LOS) and discharge to long-term care facility (LTCF).
RESULTS: Cirrhotic patients had higher risk of in-hospital mortality (8.9% vs 2.8%, P < .001), longer LOS (11.5 ± 0.26 vs 10.0 ± 0.03 days, P < .001), and higher rate of discharge to LTCF (19.0% vs 15.7%, P < .001). Mortality was highest in patients with moderate to severe liver dysfunction (21.5% vs 6.5%, P < .001). On multivariate analysis, cirrhosis was an independent predictor of in-hospital mortality (odds ratio [OR], 3.0; 95% confidence interval [CI] 2.5-3.7) and nonhome discharge (OR, 1.7; 95% CI, 1.4-2.0). In cirrhotic patients, moderate to severe liver dysfunction was the only independent predictor of in-hospital mortality (OR, 4.03; 95% CI, 2.7-5.9), but did not predict discharge disposition.
CONCLUSIONS: Resection of GI malignancy in cirrhotics is associated with poor early postoperative and transitional outcomes, with severity of liver disease being the primary determinant of postoperative mortality. These data suggest that GI cancer operations can be performed safely in well-selected cirrhotic patients with mild liver dysfunction.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 22170573     DOI: 10.1002/cncr.26682

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis.

Authors:  Dimitrios Schizas; Spyridon Peppas; Stefanos Giannopoulos; Vasiliki Lagopoulou; Konstantinos S Mylonas; Spyridon Giannopoulos; Dimitrios Moris; Evangelos Felekouras; Konstantinos Toutouzas
Journal:  World J Surg       Date:  2020-10-18       Impact factor: 3.352

Review 2.  Upper Gastrointestinal Cancer and Liver Cirrhosis.

Authors:  Kuo-Shyang Jeng; Chiung-Fang Chang; I-Shyan Sheen; Chi-Juei Jeng; Chih-Hsuan Wang
Journal:  Cancers (Basel)       Date:  2022-05-02       Impact factor: 6.575

Review 3.  Allocation of patients with liver cirrhosis and organ failure to intensive care: Systematic review and a proposal for clinical practice.

Authors:  Katrine Prier Lindvig; Ane Søgaard Teisner; Jens Kjeldsen; Thomas Strøm; Palle Toft; Valentin Furhmann; Aleksander Krag
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

4.  Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy.

Authors:  Ayman El Nakeeb; Ahmad M Sultan; Tarek Salah; Mohamed El Hemaly; Emad Hamdy; Ali Salem; Ahmed Moneer; Rami Said; Ahmed AbuEleneen; Mostafa Abu Zeid; Talaat Abdallah; Mohamed Abdel Wahab
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

5.  Whipple's Pancreatoduodenectomy in the Background of Chronic Liver Disease (CLD): An Institutional Experience.

Authors:  Samrat Ray; Suvendu S Jena; Amitabh Yadav; Sri Aurobindo Prasad Das; Naimish N Mehta; Samiran Nundy
Journal:  Surg Res Pract       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.